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Abstract: Many fluorescent sensors are currently available for in vitro bio-physiological microscopic imaging. The ability 
to label cells in living animals with these fluorescent sensors would help translate some of these assays into in vivo appli-
cations. To achieve this goal, the first step is to establish a method for selectively labeling target cells with exogenous 
fluorophores. Here we tested whether the HaloTag® protein tagging system provides specific labeling of xenograft tumors 
in living animals. After systemic delivery of fluorophore-conjugated ligands, we performed whole animal planar fluores-
cent imaging to determine uptake in tag-expressing HCT116 xenografts. Our results demonstrate that HaloTag ligands 
containing red or near-infrared fluorophores have enhanced tumor uptake and are suitable for non-invasive in vivo imag-
ing. Our proof-of-concept results establish feasibility for using HaloTag technology for bio-physiological imaging in liv-
ing animals. 
Keywords: Fluorescent imaging, HaloTag, tumor xenograft, in vivo labeling. 
INTRODUCTION 
  The major goal of molecular imaging is to non-invasively 
monitor bio-physiological activities in living organisms. Re-
cent advancements in fluorescent probe development have 
made it possible to monitor bio-physiological changes, such 
as pH [1], ions [2], redox state [3], and membrane potential 
[4] within living cells using microscopy. Extending the use 
of such bio-physiological sensors into animal models would 
be of great interest for biomedical research and drug devel-
opment.  
  A common method used to enable fluorescence imaging 
of cells is via ectopic expression of recombinant fluorescent 
proteins, such as green-fluorescent protein (GFP), red-
fluorescent protein (RFP) and their variants [5]. Specific 
expression of fluorescent proteins can be achieved via tissue-
specific promoters or gene delivery vector systems, and their 
expression can be readily monitored both by microscopy and 
with non-invasive imaging in live animals. However, it is 
difficult to develop physiological sensors based on fluores-
cent proteins [6]. The deeply buried fluorescent core within 
the protein makes it challenging to couple fluorescence with 
sensors of external changes without adversely affecting the  
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fluorescence efficiency of the protein. Another common 
strategy for in vivo fluorescence imaging is to use fluoro-
phore-conjugated antibodies for cell labeling [7]. However, 
relatively weak binding affinities and rapid probe clearance 
make antibody-fluorophore conjugates unsuitable for stable 
and long-term staining. In addition, antibody-based probes 
are intrinsically larger than small, membrane-permeable 
fluorophores, and thus cannot be used to monitor intracellu-
lar processes. 
  The HaloTag technology provides a promising alternative 
for in vivo fluorescent labeling. Developed based on a modi-
fied bacterial haloalkane dehalogenase, the protein tag is 
capable of covalent linkage to its synthetic ligands [8]. This 
labeling is irreversible and based upon specific interaction 
with the tag protein. More importantly, because the ligand is 
comprised of a small chloroalkane linker (responsible for 
interaction with the tag) and a functional moiety, novel lig-
ands are easily made by attaching this linker to a variety of 
physiological sensors [9]. Further, compared with conven-
tional fluorescent proteins and antibody-conjugates, these 
synthetic fluorescent ligands are smaller and can be mem-
brane permeable. Of particular interest to the present study, 
monitoring of intracellular pH changes has been previous 
reported using a HaloTag ligand that contains a pH sensing 
module SNARF-1™ [10]. To further investigate the possibil-
ity of translating the HaloTag technology from in vitro cell-
based to in vivo animal applications, we performed fluores-In Vivo Fluorescent Labeling of Tumor Cells  Current Chemical Genomics, 2012, Volume 6    49 
cent labeling of tag-expressing cancer cells in living animals 
which are known to be exposed to an acidic pH eviroment 
during tumorogenesis. Using a HaloTag-expressing HCT116 
human colon cancer xenograft model and either a NIR stan-
dard fluorescent ligand or the pH sensing SNARF-1™ 
ligand, we provide proof-of-principle for tag-specific label-
ing after systemic delivery of fluorescent ligands. 
MATERIALS AND METHODS 
Fluorescence Spectrum Unmixing of SNARF HaloTag 
Ligand at Different pH 
  The SNARF HaloTag ligand is the parent structure of the 
previously described AcSNARF(06)Cl [10]. In brief, SNA-
RF-1™ (in the form of carboxylic acid, acetate, succinimidyl 
ester, Invitrogen, Carlsbad, CA) was reacted with the Halo-
Tag chloroalkane amine linker, NH2(CH2CH2O)6(CH2)6Cl, 
to form SNARF-(O6)-Cl, which is referred to as SNARF 
ligand throughout the manuscript. To determine the fluores-
cence properties of this ligand at various pH, we performed 
fluorescence imaging in a black 96-well plate using 50 g of 
the ligand in 300 L of PBS, with pH ranging from pH 5.4 to 
pH 10.8. 
  Using the IVIS Spectrum system (Caliper Life Sciences, 
Hopkinton MA), the plate was sequentially imaged with a 
fixed excitation filter at 535 nm to determine the optimal 
emission in the range from 580 nm to 840 nm (1 sec, F-stop 
= 2, small binning). The acidic and basic SNARF fluores-
cence spectra were reconstructed using spectral unmixing 
(Living Image Software Version 4.2, Caliper Life Sciences, 
Hopkinton MA). 
Cellular Labeling Using SNARF HaloTag Ligand in Vitro 
  A pCINeo-HT7 plasmid containing a cytosolic HaloTag 
protein expression cassette was stably transfected into 
HCT116 human colon cancer cells. The HaloTag-expressing 
cells (HCT116-HT) were cultured in DMEM with 10% FBS 
under selection with G418 (1mg/mL). For in vitro cell label-
ing, HCT116-HT and parental HCT116 cells were incubated 
in culture media containing 20 M of SNARF-1 ligand at 
37°C for 15 min. After three washes with PBS, cells were 
incubated with fresh media for 30 min prior to imaging on a 
Nikon Eclipse Ti inverted fluorescence microscope. 
In Vivo Spectral Characterization of SNARF HaloTag 
Ligand 
  In order to reconstruct the acidic and basic SNARF fluo-
rescence spectra in vivo, NCr nude mice were subcutane-
ously inoculated with 3 × 10
6 HCT116 (left flank) or 
HCT116–HT (right flank) cells. Animals were fed an alfalfa-
free diet to reduce background autofluorescence. After two 
weeks, each tumor-bearing mouse received a single intrave-
nous injection of SNARF ligand (1 mg dissolved in 100 l of 
20% DMSO and 80% PBS). The day after injection, sequen-
tial fluorescent images were acquired using the IVIS Spec-
trum system. With a fixed Ex 535 nm filter, we performed 
emission scanning ranging from 580 to 800 nm (1 sec, small 
binning and F-stop = 2). Using the Living Image software 
package, the tissue autofluorescence and the SNARF fluo-
rescence were unmixed and spectra for both components 
were reconstructed. We determined the optimal excitation 
wavelength by scanning from 535 to 640 nm, with a fixed 
700 nm emission filter (1 sec, F-stop = 2 and small binning). 
In Vivo Uptake of Fluorescent Ligands in HaloTag-
expressing Tumor Xenografts 
  NCr nude mice with tumor xenografts (left: HCT116; 
right: HCT116-HT) received intravenous injections of 1 mg 
SNARF ligand (in 100 l of 20% DMSO and 80% PBS). 
The ligand distribution was subsequently determined by 
fluorescence imaging 1 h (day 0), 1 day and 2 days after 
probe injection with an Ex 640/ Em 700 filter pair (1 sec, F-
stop = 2 and small binning). Statistical analysis was per-
formed using Prism (Version 5.02, GraphPad, La Jolla, CA).  
  To generate the IRDye800 HaloTag ligand, HaloTag 
chloroalkane amine linker, NH2(CH2CH2O)4(CH2)6Cl, was 
reacted with the IRDye800CW™ NHS ester (LI-COR, Lin-
coln NE) to form IRDye800-(O4)-Cl, which is referred to as 
IRDye800 ligand throughout the study. For in vivo tumor 
labeling with the IRDye800 ligand, NCr nude mice with tu-
mor xenografts on the flanks (left: HCT116; right: HCT116-
HT) received intravenous injections of 0.25 mg IRDye800 
ligand (in 200 l of 10% DMSO and 90% PBS). Ligand dis-
tribution was determined 2 h (day 0), 1 day, 2 days and 3 
days after probe injection, using an Ex 745 nm/ Em 800 filter 
set (1 sec, F-stop = 2 and small binning). Statistical analysis 
was performed using Prism. 
  All animal studies were performed under protocols ap-
proved by the DFCI ACUC. 
RESULTS 
  The SNARF-1™ conjugated ligand was first validated in 
vitro as a pH sensor. SNARF ligand was dissolved in PBS at 
various pH (from acidic pH 5.4 to basic pH 10.8) in a black 
opaque 96-well plate (Fig. 1). With a fixed excitation wave-
length at 535 nm, we scanned the plate for optimal emission 
settings (from 580 nm to 840 nm) in an attempt to distin-
guish the acidic and the basic forms of SNARF ligand   
(Fig.  1A). Using spectral unmixing, we reconstructed two 
fluorescence emission components corresponding to the 
acidic and basic spectra of the SNARF ligand (Fig. 1B). The 
reconstructed spectra indicate that the maximal emission is 
~580 nm for acidic SNARF, and ~640 nm for basic dye (Fig. 
1C). 
  To assess HaloTag function in vivo, we generated Halo-
Tag-expressing xenograft tumors. Human HCT116 colon 
cancer cells were stably transfected with a cytosolic HaloTag 
expression plasmid to form the stable cell line HCT116-HT. 
After labeling with SNARF ligand in vitro, fluorescence was 
observed in the HCT116-HT cells, but not parental HCT116 
cells (Fig. 2). 
  We next tested if the SNARF ligand can label HCT116-
HT tumors in vivo after systemic administration. Athymic 
nude mice were simultaneously inoculated with HCT116 
(left) and HCT116–HT (right) cells. After establishment of 
subcutaneous tumors, mice were intravenously injected with 
SNARF ligand. Using a 535 nm excitation filter, we per-
formed sequential emission scanning 24 h after probe injec-
tion covering the emission range from 580 to 800 nm,   50    Current Chemical Genomics, 2012, Volume 6  Tseng et al. 
 
Fig. (1). Fluorescence spectral unmixing of SNARF ligand at different pH. 
(A) SNARF ligand fluorescence was assessed across the indicated pH range by sequential imaging using a fixed excitation filter at 535 nm. 
Fluorescence emission was acquired from 580 nm to 840 nm. (B) The acidic and basic SNARF fluorescent components were reconstructed 
after spectral unmixing. A composite image was generated with green and red pseudocolors representing the acidic and basic fluorescence 
respectively. (C) The unmixed spectra of the acidic (green) and basic (red) fluorescence of SNARF in vitro. 
 
Fig. (2). SNARF ligand preferentially labels HaloTag-expressing HCT116 cells. 
The HaloTag expression cells (HCT116-HT) and non-tag expressing parental cells (HCT116) were labeled with SNARF ligand prior to fluo-
rescence microscopic imaging. Labeling by the SNARF ligand was observed homogenously in the HaloTag-expressing cells (merge). No red 
fluorescence was observed in the parental HCT116 cells. A corresponding bright-field image was acquired reveal morphology of cells. The 
width of the view is 150 m. 
(Fig. 3A). Unfortunately, there was significant interference 
from tissue autofluorescence at this excitation wavelength, 
resulting in low S/N ratios in tumors (Fig. 3B). Although 
spectral unmixing of the sequential imaging data was capa-
ble of distinguishing SNARF fluorescence from tissue auto-
fluorescence (Fig. 3C), the reconstructed SNARF spectrum 
revealed considerable overlap with autofluorescence (Fig. 
3D). Thus, the optimal settings for in vitro imaging (Ex 535 
/Em 580 for acidic and Ex 535 /Em 640) were confounded 
by significant autofluorescence in vivo. In Vivo Fluorescent Labeling of Tumor Cells  Current Chemical Genomics, 2012, Volume 6    51 
 To  decrease  autofluorescence and enhance SNARF signal 
detection  in vivo, we investigated higher excitation wave-
lengths coupled with a 700 nm emission filter. Scanning ex-
citation wavelengths spanning 535-640 nm revealed that a 
640 nm excitation resulted in intense SNARF fluorescence 
and better S/N ratios in tumors (Fig. 3E, F). In addition to 
decreased autoflourescence, the more red-shifted excitation 
and emission wavelengths enable better tissue penetration.  
  Using this optimized in vivo setting (Ex 640 nm/ Em 700 
nm), we were able to determine the kinetics of SNARF lig-
and uptake and retention in tumors (Fig. 4). After systemic 
probe injection, higher SNARF uptake was observed in the 
HaloTag-expressing tumor throughout the course of imaging 
(Fig. 4A) and HaloTag-associated signals lasted for at least 2 
days after injection (Fig. 4B). Using the fluorescent signal in 
the neck region as reference, HCT116-HT tumors exhibit 
above background fluorescence (Fig. 4B). Although it was 
determined that tag-expressing tumors had statistically sig-
nificant signal-to-noise over background (p<0.05), we did 
observe background SNARF signal in parental HCT116 tu-
mors. In addition to uptake in tumors, above-background 
signal was observed in the gastrointestinal tract 1 day after 
probe injection (Fig. 4C).  
  To further enhance sensitivity, we further explored the 
possibility of using a near-infrared ligand to improve tissue 
penetration. A HaloTag ligand was conjugated with IRdye 
Fig. (3). In vivo spectral property of SNARF HaloTag ligand. 
NCr nude mice were subcutaneously inoculated with HCT116 control (left, yellow arrow) and HCT116–HT (right, blue arrow) cells. Mice 
with established tumors received intravenous injection of SNARF-1 ligand. Sequential planar fluorescence images were acquired 1 day after 
probe injection with a fixed excitation wavelength at 535 nm. (A) Fluorescence was imaged with emission filters spanning 580-800 nm. (B) 
S/N ratios were calculated using the neck as background. (C) Two fluorescence components were reconstructed by spectral unmixing, one 
representing the tissue autofluorescence (AF) and the other representing the SNARF fluorescence. A composite image was generated using 
green and red pseudocolors for tissue AF and SNARF signals respectively. (D) The unmixed spectra for the tissue AF (green) and SNARF 
signals (red) shows considerable overlap. (E) Optimal SNARF excitation was determined spanning 535-640 nm with a fixed emission at 700 
nm. (F) Optimum excitation at 640 nm provides deeper penetration and stronger SNARF fluorescence with highest S/N ratios.  52    Current Chemical Genomics, 2012, Volume 6  Tseng et al. 
 
Fig. (4). In vivo uptake of SNARF ligand in HaloTag-expressing tumor xenografts. 
(A) NCr nude mice with HCT116 tumor xenografts (control: left, yellow arrow; HT: right, blue arrow) were intravenously injected with 
SNARF ligand. Animals were imaged 1h (day 0), 1 day and 2 days after ligand injection with an Ex 640/ Em 700 filter pair. (B) Quantitative 
presentation and statistical analysis of the imaging data. The upper panel illustrates the fluorescence efficiency of tumors. The lower panel 
indicates the relative S/N ratios of tumors, normalized using fluorescence of the neck as reference. (C) Non-selective uptake was observed in 
the gastrointestinal tracks 24h after injection. Control animals received no SNARF ligand injection. 
800CW™ (IRdye800 ligand) which has near-infrared spec-
tral properties (ex 795 nm, em 820 nm) ideally suited for in 
vivo imaging. After systemic injection of ligand, we ob-
served intense fluorescence throughout the body and tumors 
2 h after injection (Fig 5A). At this early stage, both parental 
HCT116 and HaloTag-expressing HCT116-HT tumors had 
similar fluorescence levels as a result of diffuse vascular 
biodistribution. In a fashion similar to the imaging results 
obtained from the SNARF ligand, with time we observed 
selective uptake and retention of the IRdye800 ligand in tag-
expressing tumors for at least 3 days after probe injection 
(Fig. 5B and C). In addition, HCT116-HT tumors exhibited 
signal-to-noise ratios that were significantly higher than 
HCT116 parental control tumors (p<0.001) (Fig. 5C). Simi-
lar to the SNARF ligand, we observed above-background 
signal associated with the gastrointestinal tract as early as 2 h 
after IRdye800 ligand injection (Fig. 5D). 
DISCUSSION 
  In this study, we provide proof-of-principle for using 
HaloTag-mediated fluorescence labeling of tumor cells in 
living animals. We demonstrate that flourophore-conjugated 
ligands are well tolerated after systemic delivery and there is 
selective fluorescence uptake in HaloTag-expressing tumors 
in vivo. Although the uptake was enhanced in HaloTag-
expressing tumors, we did observe some non-selective signal 
in tag-negative tumors, likely due to EPR effects (enhanced 
permeability and retention), which is commonly found in 
rapidly growing tumors. Many fluorophores demonstrate 
considerable EPR effects after systemic delivery, resulting in 
non-specific trapping within tumor stroma [11, 12]. Further, 
we also observed some non-specific fluorescent signal in the 
abdominal region. We believe that this is likely due to the 
ligands’ hydrophobicity/hydrophilicity, as well as other pa-
rameters (e.g. pKa, electric charge, aromatic size, and am-
phiphilic index) which are known to influence pharmacoki-
netics and clearance in animal models. Further, it is also pos-
sible that the conjugated ligand may interact with tissue 
components in a non-selective manner in the animal. As all 
ligands for HaloTag contain a chloroalkane in additional to 
the functional moiety, we plan to modify this region in future In Vivo Fluorescent Labeling of Tumor Cells  Current Chemical Genomics, 2012, Volume 6    53 
 
Fig. (5). In vivo uptake of IRdye800 ligand in HaloTag-expressing tumor xenografts. 
For in vivo tumor labeling with the IRdye800 ligand, NCr nude mice bearing control HCT116 (left, yellow arrow) and HCT116–HT tumors 
(right, blue arrow) on the flanks were intravenously injected with 0.25 mg of the IRdye800 ligand. (A) Planar fluorescence imaging was 
performed 1 h (day 0) and 1, 2 and 3 days after probe injection with Ex 745 nm/ Em 800 nm filters. (B) Enhanced IRdye800 fluorescence 
was observed in the HT-expressing tumors. (C) Quantitative analysis shows significant increase of IRdye800 fluorescence in HT-positive 
tumors. The left panel illustrates the fluorescence efficiency of tumors. The right panel indicates the relative S/N ratios of tumors, normalized 
to fluorescence at the neck as reference. (D) IRdye800 ligand uptake was observed in the gastrointestinal track as early as 2 h after injection. 
studies to establish a structure-activity relationship for ligand 
behavior in vivo. 
  Labeling of cells or tissues with exogenously delivered 
fluorophores is the first step toward successful in vivo physi-
ological fluorescence imaging. Several hurdles need to be 
overcome in order to make this technology more practical for 
in vivo use. In general, compared with bioluminescence 
methods, fluorescence imaging methods have higher auto-
fluorescence and thus lower signal-to-noise ratios. Spectral 
shifts resulting from microenvironmental influences (e.g., 
pH, protein binding, and pigments) also impact in vivo fluo-
rescence imaging. In addition to the ligand linker modifica-
tions mention above, another way to circumvent such issues 
is to develop fluorescent probes that are fluorescently inert 
but can be effectively activated by specific intracellular bio-
logical activities. Such “gain-of-function” fluorescence sen-
sors may significantly reduce non-specific noise, allowing 
for improved sensitivity and specificity for in vivo imaging. 
  In the current study, we tested the uptake of fluorescent 
ligands by a HaloTag protein which is small enough to reside 
throughout the interior of cell. However, fusion of HaloTag 
to proteins with precise subcellular localizations could be 
used to monitor biophysiological changes in particular sub-
cellular structures of interest, such as the nucleus, mitochon-
dria or plasma membrane. Fusion of the tag with proteins of 
better stability and longer half-life could prolong fluorescent 
signal retention with target cells. Another potential applica-
tion is to use HaloTag fusion proteins, in conjunction with 54    Current Chemical Genomics, 2012, Volume 6  Tseng et al. 
bioluminescence, for in vivo BRET imaging [13]. With the 
current success and wide adaptation of the HaloTag technol-
ogy for in vitro applications, our results suggest that the 
technology also has potential to become a versatile platform 
for in vivo imaging. 
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